Drug-eluting stents

Minerva Cardioangiologica

Volumn 50, Issue 5, 2002, Pages 419-429

  Chieffo, A ^a   Colombo, A ^a  

^a EMO GVM CENTRO CUORE COLUMBUS   (Italy)

Author keywords

Coated materials, biocompatible; Graft occlusion, vascular, prevention and control; Stents

Indexed keywords

BATIMASTAT; DACTINOMYCIN; ESTRADIOL; PACLITAXEL; RAPAMYCIN; TACROLIMUS;

ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY STENT; DRUG ELUTING STENT; DRUG POTENCY; EVALUATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METAL IMPLANTATION; MICROTUBULE ASSEMBLY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHASE TRANSITION; SIDE EFFECT; SMOOTH MUSCLE FIBER; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; FOLLOW-UP STUDIES; FORECASTING; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; STENTS; TIME FACTORS;

EID: 0036808736     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
2. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95.
3. Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998;352:673-81.
4. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-88.
5. Kastrati A, Schomig A, Elezi S, Dirschinger J, Mehilli J, Schuhlen H et al. Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation 1999;100:1285-90.
6. Hoffmann R, Mintz GS, Dussaillant GR, Popma JJ, Pichard AD, Satler LF et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-54.
7. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999;100:1872-8.
8. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-9.
9. Holmes DR, Jr., Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002;106:1243-50.
10. Donaldson KL, Goolsby GL, Kiener PA, Wahl AF. Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 1994;5:1041-50.
11. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9.
12. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
13. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:1561-5.
14. O'Keefe JH, Jr., McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 1992;19:1597-600.
15. Herdeg C, Oberhoff M, Karsch KR. Antiproliferative stent coatings: Taxol and related compounds. Semin Interv Cardiol 1998;3:197-9.
16. Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-45.
17. Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000;35:1969-76.
18. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M, Jr et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 2001;103:2289-95.
19. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-9.
20. Honda Y, Grube E, de La Fuente LM, Yock PG, Stertzer SH, Fitzgerald PJ. Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001;104:380-3.
21. Kataoka T, Grube E, Hauptmann K, Hur S, Morino Y, Hassan A et al. Prevention of restenosis by a new drug eluting stent an intravascular ultrasound substudy of the SCORE trial. Circulation. 2001;104:II-701.
22. Liistro F, Stankovic G, Di Mario C, Takagi T, Chieffo A, Moshiri S et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation. 2002;105:1883-6.
23. Grube E, Silber S, Hauptmann K. TAXUS 1 prospective, randomized, double blind comparison of NIRX TM stents coated with paclitaxel in a polymer carrier in de novo coronary lesions compared with uncoated controls. Circulation 2001;104:II-463.
24. Grube E, Serruys PW. Safety and performance of a paclitaxel-eluting stent for treatment of in-stent restenosis, preliminary results of TAXUS III trial. J Am Coll Cardiol 2002;39:58A.
25. Park S, Shim W, Ho D, Raizner A, Park S, Kim J et al. The clinical effectiveness of paclitaxel coated coronary stents for the reduction of restenosis in the ASPECT trial. Circulation 2001;104:II-464.
26. Gershlick A, Descheerder I, Chevalier B, Camezind E, Gommeaux A. Vrints C et al. Local drug delivery to inhibit coronary artery restenosis.Data from ELUTES (evaluation of paclitaxel eluting stent) clinical trial. Circulation 2001;104:II-416.
27. Poon M, Marx SO, Gallo R, Badimon JJ, Taubman MB, Marks AR. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98:2277-83.
28. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999; 99:2164-70.
29. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104:1188-93.
30. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE. Role for p27(Kip1) in Vascular Smooth Muscle Cell Migration. Circulation 2001;103:2967-72.
31. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5.
32. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study. Circulation. 2001;103:192-5.
33. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
34. Sousa J, Abizaid A. Late (two-year) follow-up from the First-in-Man (FIM) Experience after the implantation of sirolimus-eluting stents. J Am Coll Cardiol 2002;39: 21A.
35. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
36. Moses J, Leon M, Popma J, Kuntz R. The US multicenter, randomized, double blind study of the sirolimus eluting stent in coronary lesions early (30 day) safety results. Circulation. 2001;104:II-464.
37. Serruys PW, Abizaid A, Foley D, Abizaid A. Sirolimus-Eluting Stents Abolish Neointimal Hyperplasia in Patients With In-stent Restenosis:Late Angiographic and Intravascular Ultrasound Results. JACC 2002;39:37A.
38. Schofer J, Breithardt G, Kuntz RE, Popma JJ. A European multi-centre, randomised double-blind study of the sirolimus eluting stent in patientsn with de novo coronary artery lesions. Eur Heart J 2002;23:265.
39. Liu XS, Hanet C, Vandormael V, Huang YM, De Scheerder I. Study of anti-restenosis with the biodyvisio dexamethasone eluting stent (STRIDE)-a multicenter trial. Eur Heart J 2002;23:265.
40. New G, Moses J, Roubin G. The effect of 17beta-estradiol coated stents on the endothelial cell repair, intimal hyperplasia and restenosis. Eur Heart J 2001;22:483.
41. Teirstein PS. Living the dream of no restenosis. Circulation 2001 104:1996-8.